v3.26.1
Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disaggregation of Revenue [Line Items]    
Total revenue $ 139,071 $ 114,473
Biopharmaceutical and other revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 301 3,584
Biopharmaceutical revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 301 2,297
Contract manufacturing and testing    
Disaggregation of Revenue [Line Items]    
Total revenue $ 0 $ 1,287